Get notified of page updates

Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab

Treatment

Treatment study for solid tumors with a RAS mutation

Clinicaltrials.gov identifier:
NCT07397338

Phase 1/2

Study Contact Information:

For additional information, contact:

Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Details
Contact
Locations
Glossary on
off

About the Study

This study is testing whether combining a new type of targeted drug called RAS(ON) inhibitors with an drug called ivonescimab is safe and may help slow or shrink cancer in people with advanced or solid tumors that have a called a RAS mutation.

RAS(ON) inhibitors are oral targeted therapies designed to block a pathway called RAS, which plays a role in several types of  cancer. RAS(ON) inhibitors are not yet FDA‑approved and are only available through participation in a clinical trial. One  RAS(ON) inhibitor, known as daraxonrasib is available for people with advanced pancreatic cancer through a program known as . You can read more about  for daraxonrasib. 

Ivonescimab combines a type of called an with a type of known as a VEGF inhibitor that blocks the blood supply to tumors. Ivonescimab is not FDA-approved and is only available in the United States through participation in a clinical trial. 

This Study is Open To:

In order to participate, people must have the following:

  • Diagnosed with an advanced or solid tumor (such as lung or colorectal cancer).
  • Their cancer must have a known as a RAS mutation (KRAS, NRAS, or HRAS).
  • Their cancer can be seen and measured on scans.
  • They are able to take oral medication.
  • Good overall physical functioning.

Some parts of the study are for people who:

  • Have already received standard treatments and their cancer progressed, or
  • Have non‑squamous non‑small cell lung cancer with no other biomarkers with a option and have not yet received systemic treatment.

See clinicaltrials.gov for full eligibility criteria. 

This Study is NOT Open To:

People with any of the following cannot join the study:

  • Have head or neck squamous cell cancer.
  • Have a medical condition that could interfere with taking or absorbing oral medications.
  • Have had major surgery within the past 4 weeks.

What the Study Involves

Participants will receive one of the following RAS(ON) inhibitors to be taken orally (by mouth) daily:

  • Daraxonrasib
  • Elironrasib
  • Zoldonrasib

Ivonescimab is given as an injection IV (into the vein).

Some participants may also receive additional cancer treatments, depending on their cancer type, such as:

  • Platinum‑based chemotherapy with pemetrexed
  • Cetuximab

Participants will receive the study drugs and remain on the study as long as the drugs are helping and side effects are manageable.

This is an open‑label study, meaning participants and researchers know which treatments are being given.

Study Contact Information:

For additional information, contact:

Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]

Locations:

Arizona

City: Scottsdale RECRUITING
Facility: Honor Health Research Institute
Contact Info:
[email protected] 480-323-1350

California

City: Los Angeles RECRUITING
Facility: USC Norris Comprehensive Cancer Center
Contact Info:
[email protected] 323-865-0967

City: San Francisco RECRUITING
Facility: UCSF Helen Diller Family Comprehensive Cancer Center
Contact Info:
[email protected] 415-613-2945

Connecticut

City: Norwich RECRUITING
Facility: Eastern Connecticut Hematology and Oncology Associates
Contact Info:
[email protected] 860-886-8362

Kentucky

City: Lexington RECRUITING
Facility: University of Kentucky HealthCare (UK HealthCare)
Contact Info:
[email protected] 859-323-2354

Minnesota

City: Saint Paul RECRUITING
Facility: Health Partners Cancer Center at Regions Hospital
Contact Info:
[email protected] 651-254-1517

Missouri

City: St Louis RECRUITING
Facility: Siteman Cancer Center
Contact Info:
[email protected] 314-273-5919

New Jersey

City: Hackensack RECRUITING
Facility: John Theurer Cancer Center at Hackensack University Medical Center
Contact Info:
[email protected] 551-996-1777

New York

City: New York RECRUITING
Facility: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC
Contact Info:
[email protected]

City: New York RECRUITING
Facility: Icahn School of Medicine at Mount Sinai
Contact Info:
[email protected] 212-241-1013

Ohio

City: Cleveland RECRUITING
Facility: University Hospitals Cleveland Medical Center
Contact Info:
[email protected] 216-844-3951

City: Columbus RECRUITING
Facility: The Jame Outpatient Care West Campus
Contact Info:
[email protected] 614-685-7433

Oregon

City: Portland RECRUITING
Facility: OHSU Knight Cancer Institute
Contact Info:
[email protected] 503-418-3451

Pennsylvania

City: Pittsburgh RECRUITING
Facility: UPMC Hillman Cancer Center
Contact Info:
[email protected] 878-261-6102

Tennessee

City: Nashville RECRUITING
Facility: Tennessee Oncology
Contact Info:
[email protected] 615-879-6410

Texas

City: Houston RECRUITING
Facility: MD Anderson Cancer Center
Contact Info:
[email protected] 832-794-3672

City: Irving RECRUITING
Facility: NEXT Dallas
Contact Info:
[email protected] 972-893-8800

City: San Antonio RECRUITING
Facility: NEXT Oncology
Contact Info:
[email protected] 210-580-9521

Virginia

City: Fairfax RECRUITING
Facility: NEXT Virginia
Contact Info:
[email protected] 703-783-4518

Treatment

Treatment study for solid tumors with a RAS mutation

Clinicaltrials.gov identifier:
NCT07397338

Phase 1/2

Study Contact Information:

For additional information, contact:

Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]

PRINTER FRIENDLY PAGE